MX2017002900A - Terapia genica de globina para el tratamiento de hemoglobinopatias. - Google Patents

Terapia genica de globina para el tratamiento de hemoglobinopatias.

Info

Publication number
MX2017002900A
MX2017002900A MX2017002900A MX2017002900A MX2017002900A MX 2017002900 A MX2017002900 A MX 2017002900A MX 2017002900 A MX2017002900 A MX 2017002900A MX 2017002900 A MX2017002900 A MX 2017002900A MX 2017002900 A MX2017002900 A MX 2017002900A
Authority
MX
Mexico
Prior art keywords
gene therapy
global gene
treating
treating hemoglobinopathies
vectors
Prior art date
Application number
MX2017002900A
Other languages
English (en)
Inventor
Michel Sadelain
Riviere Isabelle
MANSILLA-SOTO Jorge
Wang Xiuyan
Stamatoyannopoulos George
STAMATOYANNOPOULOS John
Liu Mingdong
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MX2017002900A publication Critical patent/MX2017002900A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/40—Vector systems having a special element relevant for transcription being an insulator
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La materia en cuestión descrita en la presente invención proporciona cartuchos de expresión que permiten la expresi6n de un gen de globina o una parte funcional de los mismos, vectores que lo comprenden y células transducidas con dichos cartuchos y vectores de expresión; la materia objeto de la presente descripción proporciona además métodos para tratar una hemoglobinopatía en un sujeto que comprende administrar una cantidad eficaz de tales células transducidas al sujeto.
MX2017002900A 2014-09-04 2015-09-04 Terapia genica de globina para el tratamiento de hemoglobinopatias. MX2017002900A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462045997P 2014-09-04 2014-09-04
PCT/US2015/048698 WO2016037138A1 (en) 2014-09-04 2015-09-04 Global gene therapy for treating hemoglobinopathies

Publications (1)

Publication Number Publication Date
MX2017002900A true MX2017002900A (es) 2017-10-24

Family

ID=55440425

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002900A MX2017002900A (es) 2014-09-04 2015-09-04 Terapia genica de globina para el tratamiento de hemoglobinopatias.

Country Status (11)

Country Link
US (2) US11717579B2 (es)
EP (2) EP3620521B1 (es)
JP (3) JP6710680B2 (es)
KR (2) KR102500531B1 (es)
CN (3) CN114457076A (es)
AU (2) AU2015311681B2 (es)
BR (1) BR112017004349A2 (es)
CA (1) CA2960209C (es)
ES (1) ES2746529T3 (es)
MX (1) MX2017002900A (es)
WO (1) WO2016037138A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10590433B2 (en) 2014-03-14 2020-03-17 University Of Washington Genomic insulator elements and uses thereof
AU2017370640A1 (en) 2016-12-05 2019-07-18 The Regents Of The University Of California Optimized lentiviral vector for stem cell gene therapy of hemoglobinopathies
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
CA3057862A1 (en) * 2017-03-29 2018-10-04 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
US20200190536A1 (en) * 2017-06-02 2020-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant lentiviral vector for stem cell-based gene therapy of sickle cell disorder
AU2018378683A1 (en) * 2017-12-06 2020-07-02 Memorial Sloan-Kettering Cancer Center Globin gene therapy for treating hemoglobinopathies
WO2019213011A1 (en) * 2018-04-30 2019-11-07 The Children's Hospital Of Philadelphia Compositions and methods for hemoglobin production
WO2020112870A1 (en) * 2018-11-28 2020-06-04 Forty Seven, Inc. Genetically modified hspcs resistant to ablation regime
EP3924376A4 (en) * 2019-02-14 2022-12-14 The Regents Of The University Of California OPTIMIZED LENTIVIRAL VECTOR COMPRISING MINIMUM ENABLING SEQUENCE ELEMENTS FOR HEMOGLOBINOPATHY STEM CELL GENE THERAPY
WO2020176712A1 (en) * 2019-02-28 2020-09-03 The Regents Of The University Of California Augmentations to lentiviral vectors (cclc-mgata/ank-core lcr-beta-as3-fb) to increase expression
CN110042124A (zh) * 2019-04-25 2019-07-23 国家卫生健康委科学技术研究所 基因组碱基编辑增加人红细胞中胎儿血红蛋白水平的试剂盒及应用
CN109999053B (zh) * 2019-04-26 2021-03-23 周德旺 曲氟尿苷或曲氟尿苷替匹嘧啶组合物的医药用途
CN110106203B (zh) * 2019-05-24 2023-08-11 中国医学科学院血液病医院（血液学研究所） 一种新型hbb过表达载体及其设计方法和应用
CN110699381A (zh) * 2019-09-17 2020-01-17 合肥瑞灵生物科技有限公司 地中海贫血病基因治疗载体构建方法及其用途
US20220411822A1 (en) * 2020-01-22 2022-12-29 Altius Institute For Biomedical Sciences Novel Erythroid Specific Enhancers and Uses Thereof
JP7031690B2 (ja) * 2020-01-27 2022-03-08 株式会社三洋物産 遊技機
WO2022212720A1 (en) * 2021-03-31 2022-10-06 Sigilon Therapeutics, Inc. Genetically modified human cell lines and uses thereof
CN113106098B (zh) * 2021-04-21 2022-04-01 贵州医科大学 一种在红系细胞中特异表达人β珠蛋白的重组序列及其应用
CN113564248A (zh) * 2021-09-26 2021-10-29 北京贝瑞和康生物技术有限公司 同时检测hba1/2、hbb和hbd基因位点多种突变的方法和试剂盒
CN114457119B (zh) * 2022-04-11 2022-08-12 中吉智药(南京)生物技术有限公司 慢病毒载体在制备治疗β-地中海贫血药物中的应用
CN116271106B (zh) * 2023-05-24 2023-08-11 中吉智药(南京)生物技术有限公司 慢病毒载体LentilAlpha在制备治疗α-地中海贫血药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
EP0641192B1 (en) 1992-05-18 1997-07-23 Minnesota Mining And Manufacturing Company Transmucosal drug delivery device
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
IL132105A0 (en) 1998-12-24 2001-03-19 Yeda Res & Dev Caspase-8 interacting proteins
US7541179B2 (en) * 2001-06-29 2009-06-02 Memorial Sloan-Kettering Cancer Center Vector encoding human globin gene and use thereof in treatment of hemoglobinopathies
WO2003106635A2 (en) * 2002-06-13 2003-12-24 Regulome Corp Functional sites
US20080069805A1 (en) * 2005-05-18 2008-03-20 Williams Bruce M Use of stem cells to cure genetic diseases in humans cure for sickle cell anemia
US9018011B2 (en) * 2007-02-15 2015-04-28 The United States As Represented By The Secretary Of The Department Of Health And Human Services Gamma satellite insulator sequences and their use in preventing gene silencing
US8790345B2 (en) 2007-08-21 2014-07-29 Zimmer, Inc. Titanium alloy with oxidized zirconium for a prosthetic implant
US20090156534A1 (en) * 2007-09-13 2009-06-18 Memorial Sloan-Kettering Cancer Center Globin lentiviral vectors for treatment of disease
US20110294873A1 (en) * 2008-10-23 2011-12-01 Université de Lausanne Gene Transfer Vectors Comprising At Least One Isolated DNA Molecule Having Insulator Or Boundary Properties And Methods To Identify The Same
WO2010113037A1 (en) 2009-04-03 2010-10-07 Centre National De La Recherche Scientifique Gene transfer vectors comprising genetic insulator elements and methods to identify genetic insulator elements
CA2798988C (en) 2010-05-17 2020-03-10 Sangamo Biosciences, Inc. Tal-effector (tale) dna-binding polypeptides and uses thereof
EP2880752B1 (en) 2012-08-03 2016-12-21 ABB Schweiz AG Overload limitation in peak power operation
WO2014026110A2 (en) * 2012-08-10 2014-02-13 Bluebird Bio, Inc. Compounds for improved viral transduction
US8823480B2 (en) 2012-08-10 2014-09-02 Tyco Electronics Corporation Planar electronic device
WO2014043131A1 (en) * 2012-09-14 2014-03-20 The Regents Of The University Of California Lentiviral vector for stem cell gene therapy of sickle cell disease
CA2938419A1 (en) * 2014-01-30 2015-08-06 Children's Hospital Medical Center An improved fetal hemoglobin for genetic correction of sickle cell disease
US10590433B2 (en) * 2014-03-14 2020-03-17 University Of Washington Genomic insulator elements and uses thereof

Also Published As

Publication number Publication date
EP3620521A1 (en) 2020-03-11
KR20230030002A (ko) 2023-03-03
AU2015311681A1 (en) 2017-04-13
WO2016037138A8 (en) 2017-03-16
JP2022107736A (ja) 2022-07-22
AU2015311681A8 (en) 2019-08-08
AU2015311681B2 (en) 2021-09-23
JP6710680B2 (ja) 2020-06-17
JP2020079327A (ja) 2020-05-28
ES2746529T3 (es) 2020-03-06
EP3189143A1 (en) 2017-07-12
CN107208093B (zh) 2022-03-01
JP7158427B2 (ja) 2022-10-21
US20240066148A1 (en) 2024-02-29
CN114480393A (zh) 2022-05-13
JP2017532023A (ja) 2017-11-02
KR102500531B1 (ko) 2023-02-17
CA2960209A1 (en) 2016-03-10
AU2021290257A1 (en) 2022-01-27
KR20170044752A (ko) 2017-04-25
BR112017004349A2 (pt) 2017-12-05
CA2960209C (en) 2023-08-29
CN114457076A (zh) 2022-05-10
WO2016037138A1 (en) 2016-03-10
CN107208093A (zh) 2017-09-26
US11717579B2 (en) 2023-08-08
US20170173185A1 (en) 2017-06-22
EP3189143B1 (en) 2019-08-07
EP3620521B1 (en) 2024-05-29
EP3189143A4 (en) 2018-03-21

Similar Documents

Publication Publication Date Title
MX2017002900A (es) Terapia genica de globina para el tratamiento de hemoglobinopatias.
NZ765695A (en) Immune cell organoid co-cultures
MX2019000205A (es) Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno.
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
SA520412637B1 (ar) B7 الفيروس الغدي الحال للورم المشفِّر لبروتين
MX2020005701A (es) Células efectoras inmunitarias potenciadas y usos de las mismas.
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
HK1252821A1 (zh) 用於治療具有rtk突變細胞的患者的組合物和方法
MX2018006116A (es) Materiales y metodos para el tratamiento de miopatias basadas en titina y otras titinopatias.
PH12018500810A1 (en) Antibody agents specific for human cd19 and uses thereof
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
GB2557123A (en) Modified cells and methods of therapy
MX2017001008A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
SG10201808258SA (en) Improved methods for manufacturing adoptive cell therapies
SG10201810150UA (en) Compositions and methods for enhanced gene expression in cone cells
BR112018008503A2 (pt) método para tratar câncer de pulmão de células pequenas, método para tratar um sujeito, método para selecionar um sujeito com câncer
PH12019501010A1 (en) Arginase inhibitor combination therapies
SG10201902594QA (en) Peptidomimetic macrocycles and uses thereof
NZ761006A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
MX2013014544A (es) Vectorales de terapia genica para adrenoleucodistrofia y adrenomieloneuropatia.
MX2015013181A (es) Anticuerpos humanos pac1.
MX2019004487A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
PH12019502036A1 (en) Peptides and methods for the treatment of diabetes
EP3998341A3 (en) Adenoviral vectors